Clearside BioMedical Revenue and Competitors
Estimated Revenue & Valuation
- Clearside BioMedical's estimated annual revenue is currently $7.6M per year.
- Clearside BioMedical received $20.0M in venture funding in December 2015.
- Clearside BioMedical's estimated revenue per employee is $195,846
- Clearside BioMedical's total funding is $123.9M.
- Clearside BioMedical has 39 Employees.
- Clearside BioMedical grew their employee count by -13% last year.
Clearside BioMedical Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Clearside BioMedical?
Clearside Biomedical, Inc., is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside's proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight threatening disease often occurs. The company's unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations. Clearside's pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis, retinal vein occlusion, DME and wet age-related macular degeneration. Clearside's most advanced program is in non-infectious uveitis and it expects to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for use of suprachoroidal CLS-TA in non-infectious uveitis by the end of 2018. Clearside is headquartered in Alpharetta, GA. For more information, please visit http://www.clearsidebio.com.keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Clearside BioMedical News
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical, Inc is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the...
Clearside Biomedical announced in 2021 that XIPERE (triamcinolone acetonide injectable suspension) was approved for the treatment of macular...
SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the ...
SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand t ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Clearside BioMedical Funding